Lupus nephritis: more answers needed Lupus nephritis (LN) is associated with high morbidity and mortality. It accounts for 14-47% of deaths in systemic lupus erythematosus (SLE) (Kitridon 1981) . Much has been learnt since the introduction of renal biopsy in the early 1950s and immunological studies in the 1960s. However, although new information has raised important questions, little progress towards providing the answers has been made in recent years.
The prevalence of LN in SLE is not defined. Patients without clinical, urinary or serological changes have been shown to have histological evidence of LN in the kidney. Nearly all patients without histological change have immune deposits of IgG or IgM in the mesangium and some have these deposits in the subepithelial region of the glomerular basement membrane. As IgM deposits in end-stage kidneys have no specific significance, it is unclear if mesangial deposits of IgM alone in a patient with SLE should be considered as LN.
The prevalence of the different types of LN according to the WHO classification varies in different centres. There are ethnic and regional differences in the severity, behaviour and types of target organ change of SLE (Kaslow & Masi 1978 , Serdule & Rhoads 1979 . Even in the same region the prevalence is uncertain since renal biopsies are not performed at the same stage of the LN or the systemic disease. Moreover, the renal lesions may transform from one type to another (Ginzler et al. 1980 ) with or without treatment. Amongst our patients having renal biopsies about 10% have crescenteric LN (over 70% crescents). Some who have had longstanding partially treated disease show a mixed picture of proliferation, membranoproliferative, membranous and sclerotic change. Many patients with severe systemic disease also have immune deposits in the arterioles and tubular basement membrane, with interstitial mononuclear cell infiltrate and fibrosis. The various lesions are no longer considered distinct entities but part of the spectrum of LN. Some insight has been gained into the pathogenesis of the main types of changes (Couser et al. 1982 ). There are, however, still many important questions which remain unanswere4. Is it the systemic disease, the physiochemical properties of immune complexes or intrinsic glomerular and renal factors that determine the initial lesion, the timing and nature of the transformation, and the pattern of the final renal disease? How does treatment modify these lesions? What is the optimum stage at which treatment should be initiated to achieve the best results with the least hazards?
Renal biopsy has been extensively used to document the different types of renal changes. Clinical, urinary and serological findings now enable us to predict with some certainty the type of LN a patient may have. However a 20% error may occur and this margin of error increases when patients have-had partial treatment. In a recent series renal biopsy was shown to provide guidance mainly for aggressive treatment and prognosis for irreversible renal insufficiency or failure (Whiting O'Keefe et al. 1982) . Sequential renal biopsies are needed to justify prolonged treatment. It is difficult to distinguish the patients with membranous change from those with a sclerotic lesion and hyperperfusion. It is also difficult to distinguish those with residual mixed changes from those with relapse of severe LN when the patient has no systemic or serological changes. Such patients present with a clinical picture of acute-on-chronic renal failure but respond well to aggressive intravenous methylprednisolone pulse therapy and immunosuppression. Renal biopsy will continue to be essential for the study of the pathogenesis and management of LN. Despite the complications, the use of high-dose corticosteroid therapy for Group IV (diffuse proliferative) lesions is well accepted. Side effects may be reduced by instituting alternate-day therapy (or maintaining a small dose on the odd day and a large one on the even day) as soon as the acute toxic illness is controlled. Patients become more compliant. Many patients are able to discontinue treatment although some have abnormal serology (positive antinuclear antibody, anti-DNA antibody and low C4 levels). However all patients require follow up, and must be warned about sudden relapses even after many years. Some workers maintain their patients on low-dose steroids for life. Whether this small dose makes any difference is uncertain.
For toxic patients with multiple-organ disease pulse therapy with methylprednisolone is lifesaving. The therapy may by repeated. The effect on the extrarenal disease is so dramatic that there is no urgency to provide plasmapheresis. The LN is usually improved and in some resolves completely.
The debate continues about the use of immunosuppressives because of the complications. Should they be introduced early or only after corticosteroids have failed? Which immunosuppressive drug should be used? Cyclophosphamide has the widest support but azathioprine, chlorambucil and nitrogen mustard have their advocates. This discrepancy may arise from failure to standardize the types of LN and degrees of severity before treatment, and from choosing the wrong end points as markers of efficacy. The survival of patients is not an adequate marker. Immunosuppressives have been shown to reduce the tendency to chronicity of LN and provide a i) 1985 The Royal Society of Medicine Journal ofthe Royal Society ofMedicine Volume 78 August 1985 617 more stable long-term course of the renal disease (Balow et al. 1984) . If they were given early, would the outcome of the renal disease be better?
The progress and response to treatment of the various forms of LN are not always predictable. This may be due to the different degrees of severity of the disease when treatment is initiated. Patients with severe proliferative LN have recovered, while some transform to Group V disease. Some of our patients with crescenteric LN have also recovered, yet others with milder Group IV lesions have not. The prognosis of those with Group V disease is considered good but these patients may develop severe extrarenal complications and some develop early renal insufficiency (Wang & Looi 1984) . Group III lesions were at one time considered benign but we now know they may transform to Group IV lesions, which have a poor prognosis if untreated. Should patients with Groups I, II and III types of lesions be treated? How do we recognize early transformation to Group IV? Why do some patients never develop the more severe forms of LN? By what mechanism are their kidneys protected?
In our centre where all types of SLE patients are seen in one clinic, 319 patients have been followed prospectively since 1974: 18.7% of patients have never developed clinical LN; 47.7% of patients with autoimmune haemolytic anaemia have clinical LN, whereas 87.6% of those with autoimmune thrombocytopenia have overt LN. In some patients with only antibody to Ro ribonucleoprotein, renal disease is uncommon even though they have obvious and serious extrarenal disease (Hughes 1984) . The investigation of patients protected from overt renal disease may throw some light on those who develop LN.
After 20 years we realize that the different forms of LN are part of one renal disease. We need to remember that LN is part of a systemic disease. There are too many variables that determine the outcome of LN. Some of them include the extrarenal disease, the underlying immunological process, the duration of the disease, the type of treatment, and even the idiosyncrasies of the patients and their physician(s). An integrated approach may help us arrive at a better understanding and management of SLE and of LN. ' 
